23rd Edition · Conference Agenda

Drug Discovery Strategic Summit 2026

28th – 29th October 2026 Berlin, Germany
DAY 1
Wednesday, 28th October 2026 | Berlin, GermanyDiscovery, AI & Early R&D
Registration Time
8:00 AM - 8:45 AM
Chairperson Address
8:45 AM - 9:00 AM
Keynote 019:00 AM - 9:25 AM

Drug discovery for brain diseases: low-throughput screening and AI

PB
Pieter Van Bokhoven
CSO
Amsterdam UMC
Keynote 029:25 AM - 9:50 AM

Translational R&D Excellence: Integrating ADME, DMPK & IVIVE for Success

JL
Johan Luthman
EVP & Head R&D
Lundbeck

SPONSOR PRESENTATION

9:50 AM - 10:10 AM

Using AI and Retrosynthesis To Streamline Small Molecule Discovery

At the heart of our mission is a dedication to transforming drug discovery through innovation and collaboration. We’re building an integrated technology ecosystem - merging advanced AI decision tools with a global supply network of critical chemicals - to empower researchers to accelerate the journey from scientific discovery to therapeutic breakthroughs.

In this presentation, we’ll walk through an integrated digital Design–Make–Test–Analyze (DMTA) cycle using ADDISON™ for generative molecule design and predictive ADMET modelling, and SYNTHIA® for retrosynthetic and library synthesis planning. This iterative workflow enables faster decision-making, better compound prioritization, and closer alignment between design and synthesis.

AC
Aurélie Chambon
Digital Chemistry Solutions
Merck
Coffee Break in Networking Session 10:10 AM - 10:20 AM

PRE SCHEDULE MEETINGS

01
MEETING10:20 - 10:45 AM
02
MEETING10:45 - 11:10 AM
03
MEETING11:10 - 11:35 AM
04
MEETING11:35 - 12:00 PM
LUNCH BREAK
12:00 PM - 1:00 PM
Keynote 031:00 PM - 1:25 PM

Bridging the innovation gap: new strategies to overcome antimicrobial resistance

RM
Robert Macsics
CEO
smartbax

SPONSOR PRESENTATION

1:30 PM - 1:50 PM

Development of fully human antibodies to Her-2 domains and their applications as antibody drug conjugates.

GS
Ginette Serrero
CEO
Precision Antibody
Keynote 041:50 PM - 2:15 PM

Advancing the Next Generation of Precision Cancer Therapy

BV
Balakumar Vijayakrishnan
Director, Bioconjugation and Analytical
AstraZeneca

PRE SCHEDULE MEETINGS

01
MEETING2:15 - 2:40 PM
02
MEETING2:40 - 3:05 PM
03
MEETING3:05 - 3:30 PM

PANEL DISCUSSION

3:30 PM - 4:15 PM

Bridging Science and Strategy: Advancing Drug Discovery

NP
Nishant Pandey
COO & Deputy CEO
Quercis Pharma
MC
Marcelino Arciniega Castro
Lead of Structural Biology and Data Analysis
JJP Biologics
OH
Dr. Oliver Hill
Senior Director Protein Engineering
Yumab GmbH

SPONSOR PRESENTATION

4:15 PM - 4:35 PM

Three lessons from building AI-first delivery for the software around the science.

The hidden reason AI adoption is accelerating while delivery results lag behind.

What separates successful AI-first teams from those stuck in endless experimentation.

How leading pharma and biotech organizations can scale software delivery around the science.

SA
Sebastian Andruszczak
Chief Growth Officer
Holisticon Poland
Keynote 054:35 PM - 5:00 PM

Precision Oncology 2.0, the Next Frontier in Drug Discovery

RF
Rafik Fellague-Chebra
Executive Global Head
Novartis
COCKTAIL PARTY
END OF DAY 1
DAY 2
Thursday, 29th October 2026 | Berlin, GermanyOptimization, Medicinal Chemistry & Translation
Registration Time
8:00 AM - 8:45 AM
Chairperson Address
8:45 AM - 9:00 AM
Keynote 019:00 AM - 9:25 AM

Beyond Pain: Building the Next Generation of Neuroscience Innovation at Grünenthal

KS
Klaus Baek Simonsen
Senior Vice President & Global Head of Research
Grünenthal
Keynote 029:25 AM - 9:50 AM

From (Bio)molecular Design to AI-driven Optimization - Digital Innovation in the Group Science and Technology Office

MS
Marc Siggel
Head of Digital Chemistry
Merck
Keynote 039:50 AM - 10:15 AM

Polypharmacology by Design: Combination Strategies for Complex Disease

DM
Dan Miles
CEO
Phantom Therapeutics
Keynote 0410:15 AM - 10:40 AM

Nebaprubart (JJP-1212) - Advancing a first-in-class anti-CD89 antagonist

TS
Tomasz Sitar
Head of Drug Discovery
JJP Biologics
Coffee Break in Networking Session 10:40 AM - 10:45 AM

PRE SCHEDULE MEETINGS

01
MEETING10:45 - 11:10 AM
02
MEETING11:10 - 11:35 AM
03
MEETING11:35 - 12:00 PM
LUNCH BREAK
12:00 PM - 1:00 PM
Keynote 051:00 PM - 1:25 PM

How can we develop oligonucleotide therapeutics in the CNS space.

KH
Kerstin Hofer
Principal Scientist
Roche
Keynote 061:25 PM - 1:50 PM

Emerging Modalities & Advanced Therapeutics

JB
Julia Behnke
Chief Executive Officer
Ingineeon
CLOSING REMARKS
END OF DAY 2